1. Home
  2. CBIO vs LOVE Comparison

CBIO vs LOVE Comparison

Compare CBIO & LOVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CBIO
  • LOVE
  • Stock Information
  • Founded
  • CBIO 2003
  • LOVE 1998
  • Country
  • CBIO United States
  • LOVE United States
  • Employees
  • CBIO N/A
  • LOVE N/A
  • Industry
  • CBIO
  • LOVE Other Specialty Stores
  • Sector
  • CBIO
  • LOVE Consumer Discretionary
  • Exchange
  • CBIO Nasdaq
  • LOVE Nasdaq
  • Market Cap
  • CBIO 209.8M
  • LOVE 209.8M
  • IPO Year
  • CBIO N/A
  • LOVE 2018
  • Fundamental
  • Price
  • CBIO $12.35
  • LOVE $13.98
  • Analyst Decision
  • CBIO Strong Buy
  • LOVE Strong Buy
  • Analyst Count
  • CBIO 5
  • LOVE 5
  • Target Price
  • CBIO $25.60
  • LOVE $30.00
  • AVG Volume (30 Days)
  • CBIO 111.3K
  • LOVE 568.0K
  • Earning Date
  • CBIO 11-23-2025
  • LOVE 12-11-2025
  • Dividend Yield
  • CBIO N/A
  • LOVE N/A
  • EPS Growth
  • CBIO N/A
  • LOVE 33.72
  • EPS
  • CBIO N/A
  • LOVE 0.79
  • Revenue
  • CBIO N/A
  • LOVE $690,298,000.00
  • Revenue This Year
  • CBIO N/A
  • LOVE $6.93
  • Revenue Next Year
  • CBIO N/A
  • LOVE $7.52
  • P/E Ratio
  • CBIO N/A
  • LOVE $17.69
  • Revenue Growth
  • CBIO N/A
  • LOVE N/A
  • 52 Week Low
  • CBIO $9.81
  • LOVE $12.12
  • 52 Week High
  • CBIO $21.40
  • LOVE $39.49
  • Technical
  • Relative Strength Index (RSI)
  • CBIO 49.46
  • LOVE 34.26
  • Support Level
  • CBIO $12.30
  • LOVE $14.63
  • Resistance Level
  • CBIO $12.84
  • LOVE $15.28
  • Average True Range (ATR)
  • CBIO 0.72
  • LOVE 0.54
  • MACD
  • CBIO 0.07
  • LOVE 0.02
  • Stochastic Oscillator
  • CBIO 66.55
  • LOVE 22.88

About CBIO Crescent Biopharma Inc. Common Stock

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

About LOVE The Lovesac Company

The Lovesac Co designs, manufactures and sells alternative furniture which is comprised of modular couches called sactionals and premium foam beanbag chairs called sacs. It also offers other accessories such as sactional-specific drink holders, Footsac blankets, decorative pillows, fitted seat tables, and ottomans. Its products are sold across the United States through its website or company-owned retail stores which are used in homes and offices. The majority of the firm's revenue is derived from the sale of Sactionals.

Share on Social Networks: